Bulletin
Investor Alert

Cyclerion Therapeutics Inc.

NAS: CYCN

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Cyclerion Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 25, 2022, 4:47 p.m.

CYCN
/zigman2/quotes/207301221/composite

$

1.25

Change

+0.01 +0.81%

Volume

Volume 101

Quotes are delayed by 20 min

/zigman2/quotes/207301221/composite

Today's close

$ 1.30

$ 1.24

Change

-0.06 -4.62%

Day low

Day high

$1.17

$1.29

Open

52 week low

52 week high

$1.13

$6.90

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Cyclerion Therapeutics Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20162017201820192020 5-year trend
Sales/Revenue ---4.51M2.3M
Cost of Goods Sold (COGS) incl. D&A 2.17M1.75M1.53M--
COGS excluding D&A -----
Depreciation & Amortization Expense 2.17M1.75M1.53M2.7M2.3M
Depreciation 2.17M1.75M1.53M2.7M2.3M
Amortization of Intangibles -----
Gross Income (2.17M)(1.75M)(1.53M)--
20162017201820192020 5-year trend
SG&A Expense 61.38M92.18M113.72M121.91M77.03M
Research & Development 50.9M78.8M87.72M95.14M56.41M
Other SG&A 10.48M13.37M26.01M26.77M20.62M
Other Operating Expense -----
Unusual Expense ---4.19M1.2M
EBIT after Unusual Expense ---(124.29M)(78.23M)
Non Operating Income/Expense ---(751,000)429,000
Non-Operating Interest Income ---2.03M-
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income (63.55M)(93.92M)(115.25M)(123.01M)(77.8M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (63.55M)(93.92M)(115.25M)(123.01M)(77.8M)
Minority Interest Expense -----
Net Income (63.55M)(93.92M)(115.25M)(123.01M)(77.8M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (63.55M)(93.92M)(115.25M)(123.01M)(77.8M)
Preferred Dividends -----
Net Income Available to Common (63.55M)(93.92M)(115.25M)(123.01M)(77.8M)
EPS (Basic) (2.32)(3.43)(4.21)(4.49)(2.56)
Basic Shares Outstanding 27.4M27.4M27.4M27.38M30.4M
EPS (Diluted) (2.32)(3.43)(4.21)(4.49)(2.56)
Diluted Shares Outstanding 27.4M27.4M27.4M27.38M30.4M
EBITDA (61.38M)(92.18M)(113.72M)(117.4M)(74.74M)
Copyright 2022 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Trending Tickers
  • /zigman2/quotes/207505872/composite DISH+1.05%
  • /zigman2/quotes/204151124/composite CURE-1.23%
  • /zigman2/quotes/214908404/composite GFL+1.15%
  • /zigman2/quotes/204236046/composite DUST+1.32%
  • /zigman2/quotes/200683073/composite FRC+0.90%
X
Powered by StockTwits
Link to MarketWatch's Slice.